The crippling levels of attrition within the pharmaceutical industry and the associated diminishing return on investment (ROI) have resulted in a number of approaches aimed at increasing the success rates from pre-development candidate (PDC) nomination to new drug approval. The “quality” of the PDC determines development and clinical success and the key decisions taken in the discovery phase have a strong influence on overall development cost, time and ultimately the probability of delivering successful new medicines.

Evotec's new webinar series will highlight our differentiated platform and value proposition leveraging a fully integrated discovery and development continuum to enable both the invention and selection of the highest quality drug candidates. In addition to reducing timelines and overall costs, this approach has led to increased success rates from PDC nomination to clinical development with the potential to deliver much needed new medicines to patients together with significantly improved ROI.